Dr. Raymond H. Mak

Dr. Raymond Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Director of Clinical Innovation, Thoracic Radiation Oncology Disease Site Leader, and Director of Patient Safety/Quality in the Department of Radiation Oncology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute.Dr. Mak received his undergraduate degree from Cornell University and medical degree from Harvard Medical School, trained at the Harvard Radiation Oncology Residency Program, and is board certified in Radiation Oncology.Dr. Mak has over 10 years of experience in radiation treatment of thoracic malignancies including lung cancer, mesothelioma, and thymomas, and in the clinical application of advanced radiation therapy techniques including stereotactic body radiation therapy.  He has applied stereotactic body radiation therapy for novel indications including the treatment of cardiac arrhythmias. He led the implementation of MR-guided radiation therapy and adaptive radiation therapy program at BWH/DFCI in 2019 and has expertise in these innovative new treatment approaches. His research interests focus on developing genomic and imaging biomarkers to predict radiation therapy response and toxicity for lung cancer patients, and applying artificial intelligence techniques to automate radiation therapy planning and improve patient care. He has expertise in developing new methods to reduce the risk of cardiac and pulmonary toxicity for patients receiving radiation therapy.

Dr. Mak is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

His clinical research consists of co-authoring 179 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 102 articles and participated in 2 clinical trials in the study of Lung Cancer.